Heat shock protein expression in canine malignant mammary tumours

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Romanucci, Mariarita ^a   Marinelli, Alessia ^a   Sarli, Giuseppe ^b   Della Salda, Leonardo ^a  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 73; HEAT SHOCK PROTEIN 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; FREQUENCY ANALYSIS; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TUMOR CELL;

ANIMALS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION PROFILING; HEAT-SHOCK PROTEINS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33746658605     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-171     Document Type: Article

References (75)

1. Whitley D, Goldberg SP, Jordan WD: Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999, 29:748-751.
2. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW: Biological and clinical implications of heat shock protein 27000 (Hsp27): a review. J Natl Cancer Inst 1993, 85:1558-1570.
3. Welch WJ: Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 1992, 72:1063-1081.
4. Lai BT, Chin NW, Stanek AE, Ke W, Lannks KW: Quantitation and intracellular localization of the 85 kDa heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984, 4:2802-2819.
5. Sreedhar AS, Kalmar E, Csermaly P, Shen Y: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004, 562:11-15.
6. Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
7. Conroy SE, Latchman DS: Do heat shock proteins have a role in breast cancer? Br J Cancer 1996, 74:717-721.
8. Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991, 83:170-178.
9. Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL: Heat shock protein Hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993, 85:570-574.
10. Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, Erd5, Hsp27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993, 23:239-248.
11. Ioachim E, Tsanou E, Briasoulis E, Batsis Ch, Karavasilis V, Charchanti A, Pavlidis N, Agnantis NJ: Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 2003, 12:111-119.
12. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA: Clinical and biological significance of Hsp89 alpha in human breast cancer. Int J Cancer 1992, 50:409-415.
13. Love S, King RJB: A 27kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994, 69:743-748.
14. Têtu B, Brisson J, Landry J, Huot J: Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res Treat 1995, 36:93-97.
15. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SAW: The small heat shock protein Hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 1996, 2:1199-1206.
16. Thanner F, Sütterlin HW, Kapp M, Rieger L, Kristen P, Dieti J, Gassel AM, Müller T: Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. Anticancer Res 2003, 23:1057-1062.
17. Thanner F, Sutterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, Dietl J, Gassel AM, Muller T: Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005, 25:1649-1653.
18. Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK: Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (A Southwest Oncology Group Study). Clin Cancer Res 1998, 4:1263-1266.
19. Fuqua SAW, Oesterreich S, Hilsenbeck SG, Von Hof DD, Eckardt J, Osborne CK: Heat shock proteins and drug resistance. Breast Cancer Res Treat 1994, 32:67-71.
20. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998, 79:468-475.
21. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jäättelä M: Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 2002, 62:7139-7142.
22. Bagatell R, Whitesell L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004, 3:1021-1030.
23. Faure O, Graff-Dubois S, Bretaudeau L. Derré L, Gross DA, Alves PMS, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K: Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004, 108:863-870.
24. Kim JH, Majumder N, Lin H, Chen J, Falo LD Jr, You Z: Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 2005, 11:941-949.
25. Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005, 11:1131-1138.
26. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005, 146:769-780.
27. Misdorp W: Tumors of the mammary gland. In Tumors in domestic animals 4th edition. Edited by: Meuten DJ. Ames: Iowa State Press; 2002:575-606.
28. Nieto A, Peña L, Pérez-Alenza MD, Sánchez MA, Flores JM, Castaño M: Immunohistochemical detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 2000, 37:239-247.
29. Misdorp W, Else RW, Hellmén E, Lipscomb TP: Histological classification of mammary tumors of the dog and the cat. In 2nd series Volume 7. World Health Organization AFIP. Washington: DC; 1999.
30. Gilbertson SR, Kurzman D, Zachrau RE, Hurvitz AI, Black MM: Canine mammary epithelial neoplasms: biological implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983, 20:127-142.
31. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G: Expression of Hsp90 and Cyclin D1 in human breast cancer. Cancer Lett 1999, 137:45-51.
32. Helmbrecht K, Zeise E, Reinsing L: Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000, 33:341-365.
33. cdc37 acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 1999, 19:1661-1672.
34. Aligue R, Akhavan-Niak H, Russel P: A role for Hsp90 in cell cycle control: Wee 1 tyrosine kinase activity requires interaction with Hsp90. EMB0 J 1994, 13:6099-6106.
35. Sato S, Fujita N, Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000, 97:10832-10837.
36. Pratt WB, Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997, 18:306-360.
37. Xu W, Mimnaugh E, Rosser MFN, Nicchitta C, Marcu M, Yarden Y, Neckers L: Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001, 276:3702-3708.
38. Ahern TE, Bird RC, Bird AC, Wolfe LG: Expression of the oncogene c-erbB-2 in canine mammary cancers and tumour-derived cell lines. Am J Vet Res 1996, 57:693-696.
39. Matsuyama S, Nakamura M, Yonezawa K, Shimada T, Ohashi F, Takamori Y, Kubo K: Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors. J Vet Med Sci 2001, 63:949-954.
40. Martin de las Mulas J, Ordas J, Millan Y, Fernandez-Soria V, Ramon y Cajal S: Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 2003, 80:363-367.
41. Dutra AP, Grana NV, Schmitt FC, Cassali GD: c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 2004, 37:1673-1681.
42. Gress MT, Muller-Pillasch F, Weber C, Lerch MM, Friess H, Buchler M, Beger HG, Adler G: Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res 1994, 54:547-551.
43. Yufu Y, Nishimura J, Nawata H: High constitutive expression of heat shock protein 90 alpha in human acute leukaemia cells. Leuk Res 1992, 16:597-605.
44. Münster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by Ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001, 61:2945-2952.
45. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L: Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003, 9:4961-4971.
46. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates akt kinase and sensitizes tumors to taxol. Cancer Res 2003, 63:2139-2144.
47. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ: Enhanced tumour cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004, 10:8077-8084.
48. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinanga S, Whitesell L: Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001, 7:2076-2084.
49. Kumaraguruparan R, Karunagaran D, Balachandran C, Manohar BM, Nagini S: Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta 2005, 365:168-176.
50. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferriera F, Paesmans M, Piccart M: Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001, 12:615-620.
51. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005, 23:1078-1087.
52. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005, 11:3385-3391.
53. Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
54. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW: The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamicin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005, 65:4929-4934.
55. de Carcer G: Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 2004, 64:5106-5112.
56. de Carter G, do Carmo Avides M, Lallena MJ, Glover DM, Gonzalez G: Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J 2001, 20:2878-2884.
57. Agueli C, Geraci F, Giudice G, Cimenti L, Cascino D, Sconzo G: A constitutive 70 kDa heat shock protein is localized on the fibres of spindles and asters at metaphase in an ATP-dependent manner: a new role is proposed. Biochem J 2001, 360:413-419.
58. Liao J, Lowthert LA, Ghori N, Omary MB: The 70-kDa heat shock proteins associate with glandular intermediate filaments in an ATP-dependent manner. J Biol Chem 1995, 270:915-922.
59. Jolly C, Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000, 92:1564-1572.
60. Moseley PL: Heat shock proteins and the inflammatory response. Ann N Y Acad Sci 1998, 856:206-213.
61. Polla BS, Bachelet M, Elia G, Santoro MG: Stress proteins in inflammation. Ann N Y Acad Sci 1998, 851:75-85.
62. Devaja O, King RJB, Papadopoulos A, Raju KS: Heat-shock protein 27 (Hsp27) and its role in female reproductive organs. Eur J Gynaecol Oncol 1997, 18:16-22.
63. Takahashi S, Narimatsu E, Asanuma H, Okazaki M, Okazaki A, Hirata K, Mori M, Chiba T, Sato N, Kikuchi K: Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Oncology 1995, 52:371-375.
64. Laguens GE, Coronato S, Spinelli O, Laguens RP, Di Girolamo W: Can breast cancer Hsp27 (Heat Shock Protein 27000) expression influence axillary lymph node status? Breast 2001, 10:179-181.
65. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SAW: The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 1997, 17:113-123.
66. Rust W, Kingsley K, Petnick T, Padmanabhan S, Carper SW, Plopper GE: Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on Laminin-5. Mol Cell Biol Res Commun 1999, 1:196-202.
67. Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM, Han DC: Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 2005, 280:41439-41448.
68. Lambert H, Charette SJ, Bernier AF, Guimond A, Landry J: Hsp27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. J Biol Chem 1999, 274:9378-9385.
69. Gusev NB, Bogatcheva NV, Marston SB: Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Mosc) 2002, 67:511-519.
70. Mounier N, Arrigo A: Actin cytoskeleton and small heat shock proteins: how do they interact? Cell Stress Chaperones 2002, 7:167-176.
71. Vanmuylder N, Evrard L, Daelemans P, Dourov N: Chaperones in the parotid gland: localization of heat shock proteins in human adult salivary gland. Cells Tissues Organs 2000, 167:199-205.
72. Yaziji H, Gown AM, Sneige N: Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol 2000, 7:100-109.
73. Romanucci M, Bongiovanni L, Marruchella G, Marà M, Di Guardo G, Preziosi R, Della Salda L: Heat shock proteins (HSPs) expression in canine intracutaneous cornifying epithelioma and squamous cell carcinoma. Vet Dermatol 2005, 16:108-116.
74. Hell-Pourmojib M, Neuner P, Fischer H, Rezaie S, Kindås-Mügge I, Knobler R, Trautinger F: Differential expression of a novel gene in response to Hsp27 and cell differentiation in human keratinocytes. J Invest Dermatol 2002, 119:154-159.
75. Jonak C, Klosner G, Kokesch C, Födinger D, Hönigsmann H, Trautinger F: Subcorneal colocalization of the small heat shock protein, Hsp27, with keratins and proteins of the cornified cell envelope. Br J Dermatol 2002, 147:13-19.